Christine Blank

Dexios Corporation

3400 Center Road

Suite 300


United States

Contributing Editor Christine Blank is a freelance writer based in Florida.


Study: Shorter hospital stays with Xarelto

March 15, 2016

US hospitals using rivaroxaban (Xarelto, Janssen Pharmaceuticals) instead of warfarin (Coumadin, Bristol-Myers Squibb) to treat patients diagnosed with a venous thromboembolism (VTE) may save nearly $2,000 per patient and shorten a patient’s hospital stay by approximately 1.5 days, according to a new study.

Xarelto reduces hospital stays: Study

December 15, 2015

Hospital stays were shorter for patients treated with Xarelto (rivaroxaban) in a new study, compared to those receiving standard anticoagulants.

FDA panel backs approval of GSK's mepolizumab for severe asthma

June 17, 2015

The FDA’s Pulmonary-Allergy Drugs Advisory Committee recently recommended approval of GlaxoSmithKline Plc's drug mepolizumab (Nucala) for severe asthma patients 18 and older.

Tiotropium improved asthma symptoms in phase 3 trials

March 25, 2015

New data from Phase III trials showed that the addition of tiotropium Respimat in adult patients with mild, moderate and severe asthma who continue to experience symptoms despite the use of maintenance therapies improved lung function. Boehringer Ingelheim recently presented the new data on investigational tiotropium delivered via Respimat® inhaler at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, Texas.